In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

The Current State of Play in Connected Devices
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Aptar Pharma discusses challenges and benefits of drug repurposing
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Aptar Pharma’s Ready-to-Use Program Facilitates Development Times
Publications, Pharmaceutical, Product Solutions, Innovation & Insights

Good Medicine: Solutions for Sensitive Injectable Formulations
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions